A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A Clinical Pharmacology Study of Multiple Doses of TA-7284 in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2015

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jan 2009 Planned end date changed from Dec 2008 to Feb 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top